Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer

Annals of Oncology

Volumn 14, Issue 3, 2003, Pages 428-432

  Anelli, A ^a   Brentani, R R ^b   Gadelha, A P ^a   de Albuquerque, A Amorim ^a   Soares, F ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Breast cancer; Doxorubicin; Locally advanced; p53; Paclitaxel

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; DOXORUBICIN; ESTROGEN RECEPTOR; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; PROTEIN P53; TAMOXIFEN;

ADULT; ADVANCED CANCER; ALOPECIA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; HEART FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12244271483     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg104     Document Type: Article

References (23)

1. Holmes FA, Valero, V, Walters RS et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 1999; 10: 403-411.
2. Holmes FA, Madden T, Newman RA. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 2713-2721.
3. Gianni L, Munzone E, Capri G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 2000; 13: 2688-2699.
4. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5 (Suppl 6): S3-S6.
5. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5: 1876-1883.
6. Anelli A, Rosen PP, Francheschi D, Borgen PI. p53 gene mutations in male breast cancer. Cancer 1995; 75: 2233-2238.
7. Bonetti A, Zaninelli M, Leone R et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998; 4: 2331-2336.
8. Miller CW, Tsay C, Slamon D et al. Frequency and structure of p53 rearrangements in human osteosarcomas. Cancer Res 1990; 50: 7950-7954.
9. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 1994; 21: 29-33.
10. Hortobagyi GN, Holmes FA, Theriault RL et al. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol 1997; 24: S11-S19.
11. Hortobagyi GN, Holmes FA. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 1997; 24: S4-S7.
12. Sledge GWJ, Robert N, Sparano JA et al. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 1995; 22: 105-108.
13. Moliterni A, Tarenzi E, Capri G et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced operable breast cancer. Semin Oncol 1997; 24 (Suppl 17): 10-14.
14. Giannakakou P, Poy G, Zhan Z et al. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000; 19: 3078-3085.
15. Hamilton A, Larsimont D, Paridaens R et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 2000; 1: 233-240.
16. Blagosklonny MV, Schulte TW, Nguyen P et al. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995; 55: 4623-4626.
17. Debernardis D, Sire EG, De F et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57: 870-874.
18. 2/M arrest and apoptosis. Nature Med 1996; 2: 72-79.
19. Wu GS, El D. p53 and chemosensitivity. Nature Med 1996; 2: 255-256.
20. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
21. Eicheler W, Zips D, Dorfler A et al. Splicing mutations in TP53 in human squamous cell lines influence immunohistochemical detection. J Histochem Cytochem 2002; 50: 197-203.
22. Logullo AF, de Moura RP, Nonogaki S et al. A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. Diagn Mol Pathol 2000; 9: 35-40.
23. Allred DC, Harvey JM, Berardo M, Clack GM. Prognostic and predictive factors in breast cancer by immunohistochemistry analysis. Mod Pathol 1998; 11: 155-168.